Cite Filings / GLUE / 0000080255-26-000442
Feed Companies Filings Check
Sign in
SCHEDULE 13G/A

Statement of Beneficial Ownership

Monte Rosa Therapeutics, Inc. · Filed 2026-07-08 · Acc 0000080255-26-000442

Documents 1

  • SCHEDULE 13G/A Statement of Beneficial Ownership , xslSCHEDULE_13G_X02/primary_doc.xml

Around this filing

  • 2026-08-14 SCHEDULE 13G/A Statement of Beneficial Ownership
  • 2026-07-08 SCHEDULE 13G/A Statement of Beneficial Ownership
  • 2026-07-07 4 Chief Scientific Officer sold 6,000 shares at an average $23.31 ($139,849)
  • 2026-07-06 4 Director disposed of 1,015,000 shares (other)
  • 2026-07-06 SCHEDULE 13D/A Beneficial Ownership Report
  • 2026-07-01 4 Chief Medical Officer sold 5,407 shares at $24.50 ($132,472)
  • 2026-05-15 SCHEDULE 13G/A Statement of Beneficial Ownership

Link to a passage

At least 12 characters, not counting spaces, so the link points to one passage.

External

  • SEC EDGAR (opens in new tab)

Stakes reported in this filing

Stake history · largest stake in each 13D and 13G

  1. 2026-11-16 SCHEDULE 13G/A · Chen Yu 4.4%
  2. 2026-11-16 SCHEDULE 13G/A · BVF PARTNERS L P/IL 5.0%
  3. 2026-11-16 SCHEDULE 13G/A · Vestal Point Capital, LP 8.4%
  4. 2026-11-16 SCHEDULE 13G/A · T. Rowe Price Associates, Inc. 8.6%
Loading xslSCHEDULE_13G_X02/primary_doc.xml…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…